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Homocysteine, Methylenetetrahydrofolate
Reductase C677T Polymorphism, and Risk
of Retinal Vein Occlusion: A Meta-analysis
Stuart J. McGimpsey, MB, MRCOphth,1 Jayne V. Woodside, MA (Hons), PhD,2 Chris Cardwell, PhD,2
Mark Cahill, FRCSI, FRCOphth,3 Usha Chakravarthy, MD, PhD1,4
Objective: To assess the role of plasma total homocysteine (tHcy) concentrations and homozygosity for the
thermolabile variant of the methylenetetrahydrofolate reductase (MTHFR) C677T gene as risk factors for retinal
vascular occlusive disease.
Design: Retinal vein occlusion (RVO) is an important cause of vision loss. Early meta-analyses showed that
tHcy was associated with an increased risk of RVO, but a significant number of new studies have been published.
Participants and/or Controls: RVO patients and controls.
Methods: Data sources included MEDLINE, Web of Science, and PubMed searches and searching refer-
ence lists of relevant articles and reviews. Reviewers searched the databases, selected the studies, and then
extracted data. Results were pooled quantitatively using meta-analytic methods.
Main Outcome Measures: tHcy concentrations and MTHFR genotype.
Results: There were 25 case-control studies for tHcy (1533 cases and 1708 controls) and 18 case-control
studies for MTHFR (1082 cases and 4706 controls). The mean tHcy was on average 2.8 mol/L (95% confidence
interval [CI], 1.8–3.7) greater in the RVO cases compared with controls, but there was evidence of between-study
heterogeneity (P0.001, I2  93%). There was funnel plot asymmetry suggesting publication bias. There was no
evidence of association between homozygosity for the MTHFR C677T genotype and RVO (odds ratio [OR] 1.20;
95% CI, 0.84–1.71), but again marked heterogeneity (P  0.004, I2  53%) was observed.
Conclusions: There was some evidence that elevated tHcy was associated with RVO, but not homozygosity
for the MTHFR C677T genotype. Both analyses should be interpreted cautiously because of marked heteroge-
neity between the study estimates and possible effect of publication bias on the tHcy findings.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed
in this article. Ophthalmology 2009;116:1778–1787 © 2009 by the American Academy of Ophthalmology.Retinal vein occlusion (RVO) is an important cause of
vision loss1,2 and has been linked to an increased risk of
cardiovascular mortality and stroke.3–5 Central RVO, even
when unilateral, may be associated with reduced vision-
related quality of life.6 It has been hypothesized that ele-
vated total plasma homocysteine (tHcy) is a risk factor in
RVO,7 as in atherosclerotic disease.8,9 Although elevated
tHcy has been implicated in vascular occlusions in the
retina, a number of studies have failed to demonstrate such
a relationship.10–12
Homocysteine, a sulphur-containing amino acid, is an
intermediary product in methionine metabolism.13 It is me-
tabolized by 2 major pathways. When methionine is in
excess, tHcy follows the transsulphuration pathway, where
it is irreversibly conjugated to serine by cystathionine
-synthase in a process requiring vitamin B6 as a cofactor.
Under conditions of low methionine, tHcy is primarily
metabolized through the methionine-conserving remethyla-
tion pathway. In most tissues, tHcy is remethylated in a
process requiring methionine synthase, vitamin B12 as co-
1778 © 2009 by the American Academy of Ophthalmology
Published by Elsevier Inc.factor, and methyltetrahydrofolate as cosubstrate. The path-
way requires the enzyme methylene tetrahydrofolate reduc-
tase (MTHFR) and an adequate supply of folic acid. Genetic
and acquired abnormalities in the function of any of these
enzymes or deficiencies in folic acid, vitamin B6, or vitamin
B12 cofactors can lead to elevated tHcy levels.13 One im-
portant cause of elevated tHcy is a polymorphism in the
MTHFR C677T gene, which is common in Western popu-
lations (10%–15% of individuals homozygous for this poly-
morphism).14,15 Individuals homozygous for the thermo-
labile TT variant of MTHFR show greater levels of tHcy,
particularly when serum folate levels are low.14,15
Two meta-analyses7,16 that were previously performed
concluded that elevated plasma tHcy was probably associated
with RVO. Neither of these meta-analyses revealed a signifi-
cant association between the thermolabile TT genotype and
RVO risk.7,16 Because there has been a significant number of
further studies published,10–12,17–24 we undertook an updated
meta-analysis of published data on the relationships among
tHcy, MTHFR C677T polymorphism, and RVO. The finding
ISSN 0161-6420/09/$–see front matter
doi:10.1016/j.ophtha.2009.02.033
McGimpsey et al  Homocysteine, MTHFR, and Retinal Vein Occlusion: A Meta-analysisof a conclusive link between tHcy and RVO risk could lead to
preventative measures because folic acid supplementation can
reduce serum tHcy levels25 even in those with the thermolabile
MTHFR C677T polymorphism.26
Materials and Methods
Search Strategy and Data Extraction
Eligible studies were identified by searching MEDLINE through
OVID ONLINE using this strategy (“explode ‘Retinal Vein
Occlusion’/all subheadings”) and (“explode ‘homocysteine’ or
‘homocysteine’ keyword”) or (“explode ‘MTHFR’ or ‘MTHFR’
keyword”). A similar strategy was used in searches on Web of
Science and PubMed. On each database, the search was limited to
studies on humans published up to and including October 2007.
Abstracts were screened independently by 2 investigators
(SMcG, JW) to establish whether studies were likely to provide
relevant data based on the following criteria: (1) included labora-
tory assessment of serum or plasma tHcy concentrations; or (2)
assessed the C677T MTHFR polymorphism; and (3) compared
human subjects with and without RVO.
If abstracts were considered relevant, full articles were obtained
and examined. The reference lists of all relevant articles were
reviewed for citations to articles.
Eligible studies were assessed independently by 3 reviewers
(SMcG, JVW, CC) using a structured form to extract information
about the study (country and year of publication), study subjects
(number of cases and controls, selection of cases and controls,
age), and tHcy and MTHFR data. A number of possible indicators
of study quality were also extracted, including closeness of age-
matching of cases and controls, use of fasting glucose samples, and
pre-statement of exclusion criteria. The extracted datasets were
cross-checked before analysis was performed.
Initially, corresponding authors from each study were contacted
to ask for the original dataset used for study analysis, but this
approach had limited success, because the investigators either did
not respond to our requests for data or were unable to provide
access to original datasets.
Statistical Methods
Homocysteine. The difference in mean tHcy between the RVO
and control groups and 95% confidence intervals were calculated
for each study. In 3 studies,17,27,28 the mean and standard deviation
were estimated from formulae using the median and range.29 In
one study,30 the mean and standard deviation were estimated from
formulae using the median and interquartile range.31 In another
study,32 the standard deviation estimates were not available within
groups, so the standard error of the difference in means was
estimated from the P value of a t test.33
Because the distribution of tHcy is typically slightly skewed,
sensitivity analyses were conducted on log-transformed data where
patient-level data were available, and including only those studies
with more than 35 patients in each group (in which non-normality
would be less problematic). An additional sensitivity analysis was
conducted removing studies for which formulae were applied to
calculate the mean and standard deviations.
Methylenetetrahydrofolate Reductase. Odds ratios (OR) and
95% CIs were calculated for the MTHFR TT genotype exposure
and RVO. In one study,34 no TT genotype was observed in the
RVO group, so a correction was added to provide an estimate of
the OR35 and standard error.
The I2 statistic was used to quantify the inconsistency between
study estimates, and chi-square tests were used to formally test forheterogeneity. Publication/selection bias was investigated by
checking for asymmetry in funnel plots.36
Where appropriate, random-effect models were used to calcu-
late pooled estimates.35 Study-specific weights in the random-
effects model were calculated and scaled to percentages. The
analysis was repeated in European and non-European studies, in
studies in which fasting samples were taken, in studies in which
the cases and controls were closely age matched (to within 3
years), and in studies in which greater than 50% of the cases had
CRVO or BRVOs. The analysis was also repeated, broadly group-
ing studies by control source (details in Tables 1 and 2).
Publication bias/funnel plot asymmetry was formally tested
using Begg’s37 and Egger’s test.38 A further sensitivity analysis
was conducted using the Trim and Fill method to calculate pooled
estimates after adjustment for suspected publication bias/funnel
plot asymmetry.39 Finally, meta-regression techniques were used
to investigate the association between the study characteristics and
the observed estimates. All statistical analyses were performed
using STATA 9.0 (Stata Corporation, College Station, TX).
Results
Total Homocysteine
By using the above search criteria, we found 47 articles for tHcy
and RVO. On individual examination of each of these, 36 fitted the
inclusion criteria for tHcy.10–12,17–24,27,28,30,32,40–60 The remaining
11 articles were meta-analyses,7,16 review articles,61 commentaries/
letters,62,63 case reports,64–69 or series. On closer examination, 2
articles were duplicate publications of the same dataset,48,57
whereas a further 9 articles did not present the data in a suitable
format that could be used for meta-analysis,41,42,46,47,49–51,55,56 for
example, presenting the tHcy data as percentage of the population
with elevated levels41,42,50 or not reporting tHcy concentrations or
variance in a control groups.47
Original data were available from only a limited number of
studies (n  7).10,27,40,44,45,59,60 Thus, the patient-level data were
used only for sensitivity analyses.
For the meta-analysis of tHcy we used 25 case-control
studies, and the characteristics of these are summarized in
Tables 1 and 2. A total of 1533 RVO cases and 1708 control
subjects were included.
The forest plot for tHcy and RVO is shown in Figure 1. There
was evidence of a greater mean tHcy in the cases compared with
the controls in the majority of studies. Overall, the mean tHcy in
the cases was 2.8 mol/L (95% CI, 1.8–3.7) greater than in the
controls, but there was strong evidence of between-study hetero-
geneity (P0.001, I2  93%), suggesting the need for cautious
interpretation.
Heterogeneity persisted despite reanalysis in the following sub-
sets of studies: (a) European studies (European n  14, P0.001,
I2 90%); (b) non-European studies (non-European studies 11,
P0.001, I2  91%); (c) studies with similar cases and control
ages (number of studies  18, P0.001, I2  94%); (d) studies in
which both case and control groups contained more than 35
participants (number of studies  19, P0.001, I2  93%);
(e) studies in which no approximations were used to impute means
or standard errors (number of studies  20, P0.001, I2  92%);
(f) studies for which we had individual patient data (number of
studies  7, P0.001, I2  85%); (g) studies using only fasting
samples (number of studies 18, P0.001, I2 93%); (h) studies
with more than 50% CRVO cases (number of studies  17,
P0.001, I2  93%) and studies with less than 50% CRVO cases
(number of studies  7, P0.001, I2  90%). A further analysis
by type of controls was performed on 3 groups of studies (Table
1779
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people with cardiovascular disease were excluded (number of
studies  9, P0.001, I2  93%): studies with controls who were
patients attending hospital (usually ophthalmology outpatients
clinics but without known retinal disease) (number of studies  9,
P  0.36, I2  8%) and studies in which the control group was
unclear (number of studies  7, P0.001, I2  89%). The esti-
mates from studies in which control patients had mostly other
diseases were fairly homogenous.18,10,22,24,30,45,58,59,60 The mean
tHcy was 1.83 mol/L (95% CI, 1.3–2.3; P0.001) greater in
cases than in the controls in this group.
The funnel plot in Figure 2 did not conform to the expected
funnel shape. There is some evidence that the larger studies ob-
served smaller differences in mean between the cases and controls
than the smaller studies. The shape of the observed funnel plot
could have arisen from the non-publication of small studies, which
observed no difference in mean, or a slight reduction in mean, in
the cases compared with the controls, although other explanations
are possible. Formal tests revealed evidence of funnel plot asym-
metry perhaps due to publication bias (Begg’s test P  0.012,
Egger’s test P  0.08). However, the pooled estimate was unal-
tered (overall difference in mean  2.8 mol/L) after conducting
the Trim and Fill method to attempt to adjust for funnel plot
asymmetry/publication bias, suggesting that any such bias had
little effect on the overall findings.
Finally, meta-regression techniques demonstrated little evi-
Table 1. Characteristics of Studies Examining Plasma Homoc
First Author
(Reference)
Publication
Year
Country of
Origin Fasting n BR
Cahill45 2000 Ireland yes 61
Vine58 2000 US no 74
Larsson52a 2000 Sweden no 37
79
Pianka54 2000 Israel no 21
Martin53 2000 UK yes 60
Marcucci27 2001 Italy yes 100
Boyd30 2001 UK no 63
Brown44 2002 US yes 20b
Weger59 2002 Austria yes 84
Weger60 2002 Austria yes 78
El-Asrar40 2002 Saudi Arabia no 48
Blondel43 2002 France — 101
Marcucci28 2003 Italy yes 55
Parodi32 2003 Italy yes 31
Yildirim17 2004 Turkey yes 33b
Yaghoubi18 2004 Iran yes 25b
Atchaneeyasakul11 2005 Thailand yes 32b
Terrazzi19 2005 Italy yes 69
McGimpse10 2005 UK no 100
Lattanzio20 2006 Italy no 58
Gao23 2006 China yes 64
Gumus24 2006 Turkey yes 82
Pinna12 2006 Italy yes 75
Narayanasamy21 2007 India yes 29
Moghimi22 2007 Iran yes 54
BRVO  branch retinal vein occlusion; CRVO  central retinal vein o
aData presented in 2 age groups: 50 yrs and 50 yrs.
bIncludes others (e.g., hemi-retinal, hemispheric, macular).dence of an association (P 0.39) between the difference in mean
1780tHcy between cases and controls and the difference in mean ages
between the cases and controls.
Methylenetetrahydrofolate Reductase
We found 25 published journal articles on MTHFR and RVO, of which
18 fitted the inclusion criteria.10,19,27,28,30,32,35,41,47,49,52,59,60,70–74 Ex-
clusions were 3 case reports/series,68,75,76 2 meta-analyses,7,16 1
review,77 and 1 article reporting duplicate data.48
A total of 1082 RVO cases and 4706 controls were included in
the analysis. The Forest plot for thermolabile MTHFR polymor-
phism and RVO is shown in Figure 3. Overall there was no
evidence of any association between MTHFR and RVO (OR 
1.20; 95% CI, 0.84–1.71), but there was marked heterogeneity
(P  0.004, I2  53%) between studies.
For MTHFR, the funnel plots demonstrate the expected pattern
without significant departure from symmetry (Fig 4). There was
also no evidence of publication bias after formal testing (Begg’s
test P  0.43, Egger’s test  0.30).
Discussion
We performed a meta-analysis to determine the association
among tHcy, MTHFR C677T genotype, and RVO risk.
ne and Retinal Vein Occlusion Used in Meta-analysis: Cases
Cases
CRVO
Age, yr
Mean (SD)
Ascertainment
(Time Since Diagnosis)
40 69 (—) Hospital records (3–12 mos)
74 70 (range 40–88) Hospital records (10 yrs)
37 41 (range 20–49) Hospital records (4 yrs)
79 70 (range 50–91)
21 59 (12) Consecutive patients
36 66 (13) Consecutive patients
100 Median 59 (range 18–77) Consecutive patients (2 yrs)
63 60 (16) Consecutive patients (3 mos)
3 69 (11) Hospital records (6 mos)
0 68 (11) Consecutive patients
78 69 (11) Consecutive patients
36 45 (11) Consecutive patients (“recently
diagnosed”)
85 54 (14) Consecutive patients
26 Median 57 (range 18–82) Consecutive patients (2 yrs)
31 45 (—) Consecutive patients (1 wk)
9 61 (range 37–79) Consecutive patients (6 mos)
14 61 (12) Hospital records
11 54 (13) Consecutive patients (2 wks)
— 64 (15) Consecutive patients (1 wk)
57 68 (14) Hospital records
58 40 (10) Consecutive patients (1 yr)
64 60 (4) Consecutive patients (3 mos)
26 58 (9) Consecutive patients/hospital
records
33 64 (15) Consecutive patients
29 30 (6) Consecutive patients
54 60 (13) (1 mo)
on; SD  standard deviation.ystei
VO
21
0
0
0
24
0
0
15
84
0
12
16
29
0
20
10
15
—
43
0
0
56
42
0
0
cclusiWe found a statistically significant association between
McGimpsey et al  Homocysteine, MTHFR, and Retinal Vein Occlusion: A Meta-analysisincreased tHcy serum levels and RVO risk. We did not
find any association between MTHFR C677T genotype
and RVO risk. Although our combined estimates are
similar to 2 previous meta-analyses, the inclusion of 15
additional studies have highlighted marked heterogeneity
in the associations between studies from unidentified sources.
Also, in contrast with these previous meta-analyses, funnel
plots indicated that the association between tHcy and RVO
seems less marked in larger studies, perhaps because of pub-
lication bias.7,16
Study Heterogeneity
One of the strengths of this analysis was the exploration
of the heterogeneity of the association between tHcy and
Table 2. Characteristics of Studies Examining Plasma Homocy
First Author
(Reference)
Publication
Year
Country of
Origin Fasting n
Cahill45 2000 Ireland yes 87
Vine58 2000 US no 74
Larsson52a 2000 Sweden no 65
88
Pianka54 2000 Israel no 81
Martin53 2000 UK yes 85
Marcucci27 2001 Italy yes 100 Med
Boyd30 2001 UK no 63
Brown44 2002 US yes 20
Weger59 2002 Austria yes 84
Weger60 2002 Austria yes 78
El-Asrar40 2002 Saudi Arabia no 59
Blondel43 2002 France — 29
Marcucci28 2003 Italy yes 61 Med
Parodi32 2003 Italy yes 31
Yildirim17 2004 Turkey yes 25
Yaghoubi18 2004 Iran yes 24
Atchaneeyasakul11 2005 Thailand yes 88
Terrazzi19 2005 Italy yes 50
McGimpse10 2005 UK no 91
Lattanzio20 2006 Italy no 103
Gao23 2006 China yes 64
Gumus24 2006 Turkey yes 78
Pinna12 2006 Italy yes 72
Narayanasamy21 2007 India yes 57
Moghimi22 2007 Iran yes 51
SD  standard deviation.
aData presented in 2 age groups: 50 yrs and 50 yrs.
bStudy included 2 controls; group information represents control group u
cClassified as healthy controls, volunteers, or excluding cardiovascular di
dStudies using mainly controls with other diseases and not excluding card
eStudies in which the control group was unclear.RVO. However, our attempts to identify homogeneoussubsets were largely unsuccessful, except for a subgroup
of studies in which the control group comprised hospital
patients, making any firm conclusions difficult.
We attempted to reduce heterogeneity by considering the
geographic origin of studies, classifying them as European
and non-European, because a previous meta-analysis of
MTHFR C677T polymorphism and coronary heart disease
risk showed that heterogeneity disappeared when studies
were stratified by geographic region.78 However, this was
not observed in the current study.
Homocysteine concentrations are greater in the non-fasting
than fasting state, and therefore it is recommended that blood
samples are acquired after a period of fasting.13 This is not
always possible when opportunistic sampling methods are
used and only two thirds of the studies included in the meta-
e and Retinal Vein Occlusion Used in Meta-analysis: Controls
Controls
ge, yr
ean (SD)
Source
(Matching Criteria)
0 (—) Hospital patients, primarily cataract extraction (age)d
5 (range 37–90) Hospital patients with non-retinal vascular diagnosisd
1 (range 20–49) Unknown, “randomly selected” (age)e
0 (range 50–88)
6 (18) Unknown, “healthy adults”c
2 (15) Laboratory staff/hospital patients, no cardiovascular
diseasec
6 (range 18–84) Friends/partners, no cardiovascular disease (age, sex)c
1 (16) Clinic patientsd
0 (7) Unknown, “normal subjects” with no diabetesbe
8 (11) Hospital patients, no anterior ischemic optic
neuropathy or vasculitis (age, sex)d
9 (11) Hospital patients, no anterior ischemic optic
neuropathy or vasculitis (age, sex)d
6 (12) Healthy blood donors (age, sex)c
1 (10) Source not given, (age)e
6 (range 20–80) Friends/partners, no cardiovascular disease or venous
thromboembolism (age, sex)c
4 (—) Unknown, “volunteers” (age, sex)be
8 (range 47–72) Unknown (age, sex)e
3 (14) Clinic patients, no glaucoma, uveitis or intraocular
traumad
4 (13) Unknown, “volunteers” (age, sex)e
8 (12) Unknown, “volunteers” (age)e
8 (14) Clinic patients (primarily cataract surgery)/friends/
relatives (age, sex)d
0 (13) Hospital staffc
0 (4) Volunteers undergoing routine physical examination
(age, sex, hypertension, smoking, drinking)c
7 (10) Clinic patients with refractive errors, presbyopia, or
cataract (age, sex)d
4 (8) Friends/partners/hospital staffc
7 (5) Hospital staff/students (age, sex)c
3 (9) Clinic patients, no retinal disease (age, sex,
hypertension, diabetes, smoking)d
meta-analysis.
cular risk factors.stein
A
M
7
6
4
7
6
5
ian 5
6
7
6
6
4
5
ian 5
4
5
6
5
5
6
4
6
5
6
2
6
sed in
sease.
iovasanalysis had used fasting glucose samples. However, exclusion
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heterogeneity.
Summary statistics published by the authors were used
for the meta-analysis because patient-level data were not
available to us in the majority of the studies. However,
when we carried out a subgroup analysis that was limited to
those studies for which we had patient-level data, the esti-
Figure 1. Forest plot of studies of tHcy (mol/L) and RVO, ordered by
SD  standard deviation; tHcy  total homocysteine.
Figure 2. Funnel plot of studies of tHcy and RVO, labeled by ref-
erence number. Dashed line denotes combined mean. tHcy  total
homocysteine.
1782mates of risk increase were similar, and heterogeneity was
not reduced.
A further possible reason for heterogeneity in this
meta-analysis is that we included both branch and central
RVO, because in most of the studies a distinction was not
made between these 2 disease groups. It has been sug-
gested that, although central RVO is associated with
cardiovascular risk factors, branch RVO may be more
influenced by local factors such as atherosclerotic retinal
arteries compressing retinal veins at arteriovenous cross-
ings, and therefore the cause of these conditions may be
different.45 We did attempt to address this and repeated
the analysis in studies in which more than 50% of cases
had CRVO and in studies in which more than 50% of
cases had BRVO, but in both subgroups there was a high
level of heterogeneity and the difference in tHcy between
cases and controls in these 2 groups was similar, indicat-
ing that the role of tHcy is unlikely to differ in the cause
of these 2 conditions.
A crucial consideration in case-control studies is the
selection of the control group. An ideal control group in
a case-control study will be as similar as possible to the
cases, except that they would not have the disease being
investigated. We found wide variability in the source of
control group between the studies that could have lead to
f publication. CI  confidence interval; RVO  retinal vein occlusion;date othe observed heterogeneity of our results. The controls in
McGimpsey et al  Homocysteine, MTHFR, and Retinal Vein Occlusion: A Meta-analysisthe studies usually comprised hospital staff, healthy vol-
unteers, or patients attending hospital (usually ophthal-
mology outpatient clinics, but without known retinal dis-
ease), whereas in some studies the source of controls was not
clearly stated. There are strengths and weaknesses in the use of
either hospital- or community-based controls. tHcy has been
shown to be elevated in several diseases, including cardiovas-
cular disease, and the use of healthy controls or volunteers
(e.g., excluding those with cardiovascular disease) may en-
hance mild associations with a phenomenon referred to as the
“healthy participant effect.” Therefore, the use of hospital-
based controls may be more appropriate here because these
patients’ characteristics may be closer to that of the case group.
Figure 3. Forest plot of studies investigating the association between the
[CT] and wild-type homozygotes [CC]) and RVO using the random effect
ratio; RVO  retinal vein occlusion.
Figure 4. Funnel plot of studies investigating the association between
thermolabile MTHFR genotype (comparing TT genotype with heterozy-
gous CT and homozygous CC genotypes) and RVO.An observed greater tHcy concentration in RVO cases than in
hospital-based controls is then likely to be due to RVO rather
than the presence of other conditions. We observed less het-
erogeneity in studies that recruited their control patients from
those attending a hospital. However, even within this group of
studies there was variability in how controls were selected.
Although this subgroup did demonstrate a significant associa-
tion between tHcy and RVO, the difference between cases and
controls was lower than that observed within the overall meta-
analysis. Thus, we recommend that our results be interpreted
cautiously, because many subsets of studies were investigated.
Nonetheless, it is reassuring that the overall findings were
similar within these studies.
The difference in mean ages between the cases and
controls could account for some of the between-study
variability because there is evidence showing that tHcy
increases with age.13 For example, in one study53 cases
were on average 14 years older than their controls. How-
ever, there was no evidence of more homogenous find-
ings in the group of studies with an age difference be-
tween cases and controls of less than 3 years.
Furthermore, meta-regression showed no evidence of a
correlation between the difference in mean tHcy between
cases and controls and the difference in mean age be-
tween cases and controls. These analyses, although rather
crude, suggest that a difference in age between cases and
controls does not account for much of the variability in
the study estimates.
Limitations of the Meta-analysis
The case-control study design means that the assessment
bile MTHFR genotype (comparing TT heterozygotes with heterozygotes
el, ordered by date of publication. CI  confidence interval; OR  oddsrmola
s modof tHcy in patients at varying time intervals after the
1783
Ophthalmology Volume 116, Number 9, September 2009occlusive vascular event is methodologically weak. The
vascular occlusive event itself could increase the tHcy
concentration, and this type of reverse causality is sup-
ported by studies of tHcy and coronary heart disease in
which evidence from longitudinal cohorts demonstrate
weaker associations than those found in the case-control
scenario.8
We were also unable assess the contribution of con-
founding factors to the observed results. tHcy is elevated in
several conditions, including cardiovascular disease,8,9 and
is positively associated with renal function,13 There are a
number of dietary determinants of tHcy, including B-
vitamin status13 and fruit and vegetable intake,79,80 whereas
certain drugs and cigarette smoking can interfere with
folate/tHcy metabolism.13 Imbalances in these parameters
between cases and controls have the potential to influence
the results.
For example, we were unable to account for folate status
in this meta-analysis because it was only examined in a
small number of studies. It is therefore a possibility that
differences in folate intake between studies explain the
observed heterogeneity.
Effect of Publication Bias
For obvious reasons it is recognized that studies yielding
significant results are more likely to be published leading to
publication bias. The funnel plot (Fig 2) indicated that larger
studies observed smaller differences in mean between the
cases and controls than smaller studies. This observation
is consistent with publication bias because studies with
smaller sample sizes that may have been conducted and that
did not detect a difference between cases and controls were
not published. If this is the case, then our combined estimate
would exaggerate the true difference in mean tHcy between
the cases and controls. Alternatively, it is possible that the
funnel plot shape could have arisen because the larger
studies differed from the smaller studies with respect to
other study characteristics, such as quality. By ignoring the
funnel plot and significant heterogeneity, it would be easy to
conclude that an association exists between tHcy and RVO.
However, the marked heterogeneity in the studies, except
for the subgroup of studies that used hospital patients as
controls, and the evidence of publication bias are strong
reasons for questioning the finding that tHcy and RVO are
related.
Thermolabile Methylenetetrahydrofolate Reductase
and Retinal Vein Occlusion Risk
Because of the weaknesses in the case-control approach
outlined above (residual confounding and reverse causal-
ity), it has been proposed that a more robust method for
detecting association would be to examine the relationship
between the genetic variant MTHFR C677T and elevated
tHcy concentrations,14,15 because this will not be subject to
reverse causation or the confounding that exists in observa-
tional studies of disease risk in relation to directly measured
tHcy concentrations.78 This approach follows the principle
of Mendelian randomization.81 By examining the associa-
1784tion between MTHFR C677T genotype and RVO risk, we
found no association between homozygosity for the TT
genotype and RVO risk. Heterogeneity between studies was
high, but there was no indication of publication bias.
There are several possible explanations for this lack of
association between MTHFR and RVO risk, other than a
true lack of association. Differences in tHcy concentration
by MTHFR C677T genotype have been shown to be greater
at lower levels of folate intake and status, and are reduced
after folate supplementation.26 We did not have information
on folate status in the majority of studies and thus were
unable to account for folate status in our analysis.
Second, with 1082 cases and 4706 controls, this is still a
modestly sized meta-analysis in terms of genetic polymor-
phisms, and the power to detect a small increase in risk may
be limited.
Overall, the findings from our meta-analysis on the
lack of an association between MTHFR C677T genotype
and RVO risk are consistent with the possibility that
weaknesses in the study design may have contributed to
the observation of a positive association between tHcy
and RVO in the individual studies and the overall meta-
analysis.
Despite the inclusion of 15 additional case-control stud-
ies after initial meta-analyses,7,16 we were still unable to
draw firm conclusions on the relationship among tHcy,
MTHFR, and RVO. The majority of studies published have
tended to conclude that an association between tHcy and
RVO exists, and our meta-analysis supports this view
through the finding of a significantly increased pooled es-
timate, suggesting that reduction of tHcy with folate sup-
plementation may reduce RVO risk. However, the presence
of marked heterogeneity and clear evidence of publication
bias makes direct comparison and pooling of the results
unreliable. The pooled increase in risk due to tHcy is also
not in accord with the absence of an association between
RVO and MTHFR TT genotype. Therefore, the association
between tHcy and RVO remains tentative and requires
high-quality, well-designed epidemiologic studies, prefera-
bly of cohort design, before firm conclusions on the putative
role of elevated tHcy and MTHFR status on RVO occlusion
can be made.
In conclusion, there is evidence to suggest an association
between tHcy and RVO. Because of the presence of heter-
ogeneity and publication bias, no recommendation can be
made with regard to routine investigation and treatment of
elevated tHcy in the setting of RVO (rating CIII). There is
no evidence to suggest an association between MTHFR
C677T genotype and RVO. There was heterogeneity be-
tween groups but no evidence of publication bias. There is
no evidence to suggest routine testing of MTHFR C677T
genotype in clinical practice (rating CII).
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Documentation of how data were classified and coded (e.g., multiple raters, blinding and interrater reliability)
Assessment of confounding (e.g., comparability of cases and controls in studies where appropriate)
Assessment of study quality, including blinding of quality assessors; stratification of regression on possible predictors
of study results
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Assessment of quality of included studies
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Consideration of alternative explanations for observed results
Generalization of the conclusions (i.e., appropriate for the data presented and within the domain of the literature
review)*This study conforms to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines.
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